Physician profile
Chason E Worthy
NPI 1881734556
$11,425.92
in general payments reported to CMS, 2019-2025
33 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,836 · 2022: $2,237 · 2023: $2,123 · 2024: $2,599 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,074 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,073.69 |
| Education | $279.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,751.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,068.85 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $807.59 | 2022-2025 | Sotyktu |
| Pfizer INC. | $723.60 | 2021-2025 | |
| Dermavant Sciences, INC. | $566.73 | 2022-2024 | Vtama |
| Leo Pharma INC. | $526.84 | 2021-2025 | Adbry |
| Amgen INC. | $450.31 | 2021-2025 | Otezla, Enbrel, Otezla |
| Regeneron Healthcare Solutions, INC. | $435.63 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $415.36 | 2021-2025 | |
| Lilly USA, LLC | $394.42 | 2021-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $392.19 | 2021-2025 | Tremfya |
| Almirall LLC | $337.04 | 2021-2024 | Seysara, Klisyri |
| Incyte Corporation | $317.92 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $314.84 | 2021-2025 | |
| Ucb, INC. | $311.76 | 2021-2025 | Bimzelx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $292.90 | 2022-2025 | |
| Galderma Laboratories, L.P. | $277.24 | 2021-2025 | Nemluvio |
| Allergan, INC. | $189.45 | 2021-2022 | |
| Botanix Sb INC | $162.95 | 2025 | Sofdra |
| Epi Health, LLC | $160.80 | 2021-2022 | |
| Biofrontera INC. | $127.50 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $72.16 | 2021 | |
| Arcutis Biotherapeutics, INC. | $72.15 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $52.61 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.64 | 2021-2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.93 | 2022-2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $20.63 | 2024 | Ycanth |
| Revance Therapeutics, INC. | $20.61 | 2025 | Daxxify |
| Strata Skin Sciences, INC. | $17.89 | 2025 | Xtrac |
| Fidia Pharma USA INC. | $15.43 | 2024 | Triluron, Hyalgan, Hymovis |
| Kowa Pharmaceuticals America, INC. | $13.76 | 2022 | |
| Stemline Therapeutics INC. | $13.48 | 2021 | |
| Organon LLC | $9.78 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chason Worthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.